Personal Introduction

• Ying Shen, Professor, Principal Investigator (PI) of the Anti-tumor pharmacology Research Group, Shanghai Jiao Tong University School of Medicine; Deputy Director of the Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai (CCTS); Recipient of the Shanghai Outstanding Talent Program (Pinnacle Project, 2024); PI at the Key Laboratory of Cell Differentiation and Apoptosis, Ministry of Education; Visiting Scholar at the University of California, San Diego (UCSD). Prof. Shen earned her Bachelor’s degree from Nanjing University and Ph.D. in Pharmacology from the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS). She has been affiliated with Shanghai Jiao Tong University School of Medicine since 2009, and served as a Visiting Scholar and Postdoctoral Fellow at UCSD from 2012 to 2013.

• Her research focuses on the regulatory mechanisms of tumor metabolic enzymes and associated therapeutic strategies, including the discovery of novel drug targets and candidate drugs. Her findings have been published as corresponding author (including co-corresponding author) in high-rank SCI journals such as Cell Metabolism, Science Translational Medicine, Drug Resistance Updates, Cancer Research (cover article), Oncogene, and Acta Pharmaceutica Sinica B. She holds five authorized national invention patents (one of which has been licensed). She has led five projects funded by the National Natural Science Foundation of China and one project by the Shanghai Municipal Science and Technology Commission. Her accolades include the Second Prize of the Chinese Pharmaceutical Association Science and Technology Award (ranked 2nd) and the First Prize of the Shanghai Pharmaceutical Science and Technology Award (ranked 2nd). She currently serves as a council member of the Shanghai Pharmacological Society, a member of the Tumor Pharmacology Committee of the Chinese Pharmacological Society, and a member of the Tumor Biomarkers Committee of the China Anti-Cancer Association, among other roles.

Selected publications

1. A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small cell lung cancer. Cell Metabolism, 2019 Dec 3, 30(6):1107-1119.e8 (IF2019: 21.567，最后通讯作者)

2. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Science Translational Medicine, 2021 Oct 6, 13(614): eabg6428. (IF2021: 19.315，共同通讯作者)

3. Metabolic and non-metabolic functions of PSAT1 coordinate signaling cascades to confer EGFR-inhibitor resistance and drive progression in lung adenocarcinoma. Cancer Research, 2022 Oct 1;82(19):3516-31. (IF2022: 11.2，唯一通讯作者，封面文章)

4. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma, Drug Resistance Updates, 2023 May;68:100957. (IF2023: 15.8，最后通讯作者)

5. A Phosphoglycerate Mutase 1 Allosteric Inhibitor Restrains TAM-mediated colon cancer progression. Acta Pharmaceutica Sinica B, 2024 Jul, 14(11):4819-4831. (IF2023: 14.7，最后通讯作者)

6. GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma. Oncogene, 2024 Jul 5; 43:2504-16. (IF2023: 6.9，唯一通讯作者)

7. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2021 Jan, 42(1):115-119. (IF2021: 7.169，最后通讯作者)

8. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers. Cancer Drug Resistance, 2024, 7:38. (IF2023: 4.6，共同通讯作者，特邀专刊综述)

9. A novel allosteric site in casein kinase 2α discovered using combining bioinformatics and biochemistry methods. Acta Pharmacologica Sinica, 2017, 38(12):1691-1698. (IF2017: 3.562，共同通讯作者)

Patent:

1. Use of PGAM1 Allosteric Inhibitor HKB99 for Treating Lung Adenocarcinoma. ZL 201910284333.4.

2. 9,10-Anthraquinone Compound and Pharmaceutical Use Thereof. ZL 201810273938.9. Licensed, Contract No. 2021310031004946.

3. Use of an AKR1B Inhibitor for Treating Lung Cancer. ZL 202010498449.0.

4. Method for Heterologous Production of Linear Triterpenes. ZL 201811597099.2.

5. Use of an ENPP1 Inhibitor in Combination with an Anticancer Drug in the Preparation of an Antitumor Medicament. ZL 202010857037.1.